Wordt geladen...
Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage
Recently, immune checkpoint inhibitors (iCIs) have been used to treat cancers. Once some of the iCIs for the treatment of hepatocellular carcinoma (HCC) are certified in clinical trials, they are likely be administered to HCC patients with hepatitis C virus (HCV). However, the immunopathogenesis of...
Bewaard in:
| Gepubliceerd in: | Intern Med |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
The Japanese Society of Internal Medicine
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7578607/ https://ncbi.nlm.nih.gov/pubmed/32522918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.3726-19 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|